Research output

A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3)

Research output: Contribution to journalArticleAcademicpeer-review

Associated researcher

  • Forster, M.
  • Hackshaw, A.
  • De Pas, T.
  • Cobo, M.
  • Garrido, P.
  • Summers, Y.
  • Dingemans, A.C.

  • Flynn, M.
  • Schnell, D.
  • von Wangenheim, U.
  • Loembe, A.
  • Kaiser, R.
  • Lee, S. M.

Associated organisations

    Research areas

  • Nintedanib, Non-small cell lung cancer, Squamous, TRIPLE ANGIOKINASE INHIBITOR, CLINICAL-PRACTICE GUIDELINES, LABEL DOSE-ESCALATION, BIBF 1120, CONTROLLED-TRIAL, CARBOPLATIN, PACLITAXEL, BEVACIZUMAB, PHARMACOKINETICS, ANGIOGENESIS
View graph of relations

Details

Original languageEnglish
Pages (from-to)27-33
Number of pages7
JournalLung Cancer
Volume120
DOIs
Publication statusPublished - 1 Jun 2018